MetaCap

Eikon Therapeutics Inc. (EIKN)

NASDAQ: EIKNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

4.74-0.02 (-0.42%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EIKN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$256.84M
EPS (TTM)
-$7.86
52-week range
4.72 – 17.40
Day range
4.74 – 5.19
Volume / Avg
691.44K / 560.40K
Beta
—

52-week range

$4.72$17.40

EIKN stock today

Shares of Eikon Therapeutics (EIKN) finished lower on Nov 20 at $4.74, a drop of 0.42% or $0.02 per share, versus the S&P 500's 3.70% decline. Shares are 72.8% below their 52-week high of $17.40, set on Feb 5, 2026 and 0.4% above the 52-week low of $4.72, near the bottom of the past year's range. Eikon Therapeutics has posted a net loss over the last twelve months (EPS of -$7.86), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Eikon Therapeutics

Company profile

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Roger M. Perlmutter M.D., Ph.D.
Headquarters
Millbrae, CA
Employees
384
IPO year
2026

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$24.00+406.33%

  • Strong buy 2
  • Buy 4
  • Hold 0
  • Sell 1
  • Strong sell 0

Target range

Low $4.00High $32.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.59 vs $-1.74
Surprise
+8.62%

EIKN news

All EIKN news

Eikon Therapeutics peers

Health Care sector
EIKN peer companies
CompanyPrice% ChgMarket capCompare
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs EIKN
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs EIKN
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs EIKN
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs EIKN
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs EIKN
AGENAgenus Inc.5.97-2.77%$270.12Mvs EIKN
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs EIKN
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs EIKN

Indexes, lists and sector

Eikon Therapeutics stock FAQ

What is Eikon Therapeutics's stock price today?

EIKN last traded at $4.74 as of Nov 20, 4:00 PM EST, down 0.42% on the day. Prices are delayed at least 15 minutes.

Who is Eikon Therapeutics's CEO?

Dr. Roger M. Perlmutter M.D., Ph.D. is the chief executive officer of Eikon Therapeutics Inc., which has about 384 employees.

What is the EIKN 52-week high?

The 52-week high for EIKN is $17.40 and the 52-week low is $4.72. The stock is currently 72.8% below its high.

Compare EIKN